T1	Participants 395 424	Seventy-two cases of patients
T2	Participants 610 716	Group A (treatment group): patients with less than 30% TBSA covered with xenogenic acellular dermal matrix
T3	Participants 718 813	Group B (control group): patients with less than 30% TBSA covered with betadine ointment gauzes
T4	Participants 815 919	Group C (treatment group): patients with more than 30% TBSA covered with porcine acellular dermal matrix
T5	Participants 921 1016	Group D (control group): patients with more than 30% TBSA covered with betadine ointment gauzes
